Literature DB >> 21723955

Animal models of asthma: value, limitations and opportunities for alternative approaches.

Anthony M Holmes1, Roberto Solari, Stephen T Holgate.   

Abstract

Asthma remains an area of considerable unmet medical need. Few new drugs have made it to the clinic during the past 50 years, with many that perform well in preclinical animal models of asthma, failing in humans owing to lack of safety and efficacy. The failure to translate promising drug candidates from animal models to humans has led to questions about the utility of in vivo studies and to demand for more predictive models and tools based on the latest technologies. Following a workshop with experts from academia and the pharmaceutical industry, we suggest here a disease modelling framework designed to better understand human asthma, and accelerate the development of safe and efficacious new asthma drugs that go beyond symptomatic relief.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723955     DOI: 10.1016/j.drudis.2011.05.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  44 in total

Review 1.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 2.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

3.  Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs).

Authors:  Natalie Burden; Kathryn Chapman; Fiona Sewell; Vicky Robinson
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-03       Impact factor: 1.232

Review 4.  Alternative Animal and Non-Animal Models for Drug Discovery and Development: Bonus or Burden?

Authors:  Irlan Almeida Freires; Janaina de Cássia Orlandi Sardi; Ricardo Dias de Castro; Pedro Luiz Rosalen
Journal:  Pharm Res       Date:  2016-11-17       Impact factor: 4.200

Review 5.  Aligning mouse models of asthma to human endotypes of disease.

Authors:  Rebecca A Martin; Samantha R Hodgkins; Anne E Dixon; Matthew E Poynter
Journal:  Respirology       Date:  2014-05-09       Impact factor: 6.424

Review 6.  Key mediators in the immunopathogenesis of allergic asthma.

Authors:  Sannette Hall; Devendra K Agrawal
Journal:  Int Immunopharmacol       Date:  2014-06-13       Impact factor: 4.932

Review 7.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

8.  Interleukin 13 and the evolution of asthma therapy.

Authors:  Gabriele Grünig; David B Corry; Joan Reibman; Marsha Wills-Karp
Journal:  Am J Clin Exp Immunol       Date:  2012-06-30

9.  Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Authors:  John D Harling; Angela M Deakin; Sébastien Campos; Rachel Grimley; Laiq Chaudry; Catherine Nye; Oxana Polyakova; Christina M Bessant; Nick Barton; Don Somers; John Barrett; Rebecca H Graves; Laura Hanns; William J Kerr; Roberto Solari
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

10.  Discovery of novel aminopiperidinyl amide CXCR4 modulators through virtual screening and rational drug design.

Authors:  Yoon Hyeun Oum; Steven A Kell; Younghyoun Yoon; Zhongxing Liang; Pieter Burger; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2020-06-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.